Developing drugs to treat diseases creates opportunities to simultaneously address the urgent unmet medical needs of patient populations and access new markets.

The challenging clinical trials landscape for drugs continues to achieve new efficiencies due, in part, to streamlined regulatory processes, decentralized clinical trials models and next-generation technologies, all supported by a flexible and evolving supply chain.

You can rely on us facilitate your complex, rare disease clinical trials because we are a wholly owned subsidiary of UPS and the essential clinical part of UPS Healthcare. With Marken, BOMI Group, and Polar Speed included, the UPS Healthcare network staffs 199 locations with 10,000+ employees worldwide.